The Galician biotechnology group Zendal, known as CZ-Biofabri until the end of last year, has just announced the launch of a new subsidiary called Zinereo Pharma, which will focus entirely on the manufacturing of probiotics. This new company was created after Biofabri split up into two companies specialized in human health: Biofabri, specialized in vaccine development and manufacturing, and the new Zinereo Pharma, which will be focused on probiotics and pharmaceutical drugs, according to sources from the Porriño-based group.
In the year 2016, Zendal decided to use its extensive experience in the industrial production of microorganisms to launch a line of probiotics, and for that purpose it purchased two companies in the industry, Probisearch and Bialactis, both specialized in this type of products. The Galician group, with 272 highly qualified employees (55% of which are women), currently has three strong business lines within the biotechnology and pharmacy industry: the development and manufacturing of vaccines and other biological products; the pharmaceutical department, specialized in manufacturing and distributing pharmaceutical products on a contract basis; and the most recent one, launched through Zinereo Pharma.
The group, which sells its products in 65 countries, is already working to expand its facilities in O Porriño by building two new plants that will increase the industrial capacity of the CZ Vaccines business line. Moreover, the group is looking for a piece of land to build a new factory for human healthcare products.